Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
APL-3007 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 (APL-3007 Dose/Frequency 1 ) | EXPERIMENTAL | APL-3007 SC + pegcetacoplan (APL-2) |
| Group 2 (APL-3007 Dose/Frequency 2) | EXPERIMENTAL | APL-3007 + pegcetacoplan (APL-2) |
| Group 3 (placebo) | PLACEBO_COMPARATOR | Placebo SC + pegcetacoplan (APL-2) |
| Name | Type | Description |
|---|---|---|
| APL-3007, pegcetacoplan (APL-2) | DRUG | Complement C3 inhibitor |
| Placebo, Syfovre | OTHER | Complement C3 Inhibitor |
Inclusion Criteria: * The study eye must meet all inclusion criteria. If both eyes meet the inclusion criteria, the eye with better normal luminance visual acuity at the screening visit will be designated as the study eye. If both eyes have the same visual acuity, the right eye will be used as the ...
APL-3007 is an investigational small molecule developed by Apellis Pharmaceuticals, Inc. (ticker APLS) for geographic atrophy secondary to age-related macular degeneration, an ophthalmology condition. It is being studied in a Phase 2 clinical program and is not yet approved.
APL-3007 is being developed for geographic atrophy secondary to age-related macular degeneration, a progressive eye condition. The Phase 2 study evaluates it in combination with Syfovre (pegcetacoplan, also known as APL-2) in patients diagnosed with this condition. It remains investigational and is not approved for this use.
APL-3007 targets C3, a component of the complement system. By acting on C3, the small molecule is designed to modulate complement activity, which is relevant to geographic atrophy secondary to age-related macular degeneration. The Phase 2 trial also evaluates APL-3007 in combination with pegcetacoplan, which is itself a C3-targeted therapy.
APL-3007 is being developed by Apellis Pharmaceuticals, Inc., which trades under the ticker APLS. The company is running the Phase 2 study of APL-3007 in combination with Syfovre (pegcetacoplan, APL-2) in patients with geographic atrophy secondary to age-related macular degeneration.
APL-3007 is in Phase 2 clinical development. It is investigational and has not been approved by the FDA. The ongoing Phase 2 trial is randomized, double-blind, placebo-controlled, and currently recruiting participants.
APL-3007 is being studied in the Phase 2 trial NCT07215390, titled a study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of multidose APL-3007 in combination with Syfovre/pegcetacoplan (APL-2) in patients with geographic atrophy secondary to age-related macular degeneration. The trial is recruiting, is placebo-controlled, and plans to enroll 240 participants in the United States.
No. APL-3007 and pegcetacoplan (APL-2, marketed as Syfovre) are distinct agents. APL-3007 is a small molecule being studied in combination with pegcetacoplan in the Phase 2 trial NCT07215390 for geographic atrophy secondary to age-related macular degeneration. Both are associated with Apellis Pharmaceuticals, but they are separate drug candidates.